Cellectis, Stemgent Partner on Genome Engineering, mRNA Reprogramming | GenomeWeb

NEW YORK (GenomeWeb News) – Cellectis bioresearch, a subsidiary of Cellectis group, today said that it has partnered with Stemgent to provide research services that combine mRNA reprogramming and genome engineering.

The firms said that the combination of their technologies would "pave the way for clinically-relevant applications in regenerative medicine." Terms of the alliance were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.